900PInterim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). (23rd October 2018) - Necchi, A; Pouessel, D; Leibowitz-Amit, R; Flechon, A; Gupta, S; Barthelemy, P; Maio, M; Zhu, X; Asatiani, E; Serbest, G; Zhen, H; Loriot, Y